| Technology Name | Briefcase | Lead Researcher |
|---|---|---|
At a Glance
Ayana Pharma is uniquely positioned to expand the uses and efficacy of the lipid-based cytotoxic drug’s well-established clinical profile. Invented by Prof. Yechezkel Barenholtz from the Hebrew University who is also the co-founder ... More | Barenholz Yechezkel | |
Background
Current preclinical and clinical data indicate that there is negligible release of drug from circulating liposomes.
Once liposomes extravagate to extracellular tissue fluids, little is known of the processes determining drug release. ... More | Barenholz Yechezkel | |
Category
Life Sciences and Bio Technology
Keywords
Chemotherapy, Drug resistance * The project is conducted in collaboration with Memorial Sloan-Kettering Cancer Center.
Application
Cells with multidrug resistance (MDR) due to aberrant ... More | Barenholz Yechezkel | |
Company Name
LipoCure
Year Company was founded
2009
Company Founders
Prof. Yechezkel Barenholtz
Current CEO
Dr. Liana Patt, Ph. D., MBA
About the Company
LipoCure is developing a number of highly-potent therapeutics utilizing proprietary ... More | Barenholz Yechezkel | |
Background
Intravenous injection of some liposomal drugs, diagnostic agents, micelles and other lipid-based nanoparticles cause hypersensitivity reactions in up to 45% of patients,which appear to be initiated by the complement system (C) of ... More | Barenholz Yechezkel | |
Background
Most active pharmaceutical ingredients (APIs) are not suitable for “passive” loading into nano-liposomes. The desired concentration in the nano-liposomes is hard to achieve. Consequently, the therapeutic efficacy in humans is not ... More | Goldblum Amiram | |
Background
The physical size of protein drugs and their susceptibility to degradation are key determinates that make them more dependent on drug delivery technologies. However formulating protein delivery systems so that they maintain their ... More | Barenholz Yechezkel |